Search results
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks· 5 days agoFree Report) closed the most recent trading day at $78.99, moving +1.24% from the previous trading session. This move outpaced the S&P 500's daily gain of 0.11%. Coming into today, shares of ...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 3 days agoThe Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, signed a Memorandum of Understanding (MoU) with AstraZeneca during BIO International ...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 5 days agoAmgen is an established big pharma company with a massive pipeline and many avenues for growth...
ASCO24: Enhertu aims to replace Herceptin in first-line metastatic breast cancer
Pharmaceutical Technology via Yahoo Finance· 5 days agoInterim safety and efficacy results of the Phase Ib/II Destiny-BREAST07 trial with Enhertu...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks· 1 day agoEli Lilly's (LLY) CFO Anat Ashkenazi resigns. CHMP recommends the expanded use of AbbVie's (ABBV) Skyrizi and AstraZeneca's (AZN) Tagrisso.
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks· 1 day agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective response rate of almost 52% in certain heavily pre-treated patients with ovarian cancer.
Antibody-Drug Conjugate Picks Up Another Win in HR+/HER2-low Breast Cancer
MedPage Today· 6 days agoThe antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd, Enhertu) significantly improved...
Astra’s Enhertu delays breast cancer in patients with low HER2 levels
WHTC 1450 Holland· 6 days agoBy Deena Beasley (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to...
AstraZeneca PLC ADR TradeGate Stock Price Today | NASDAQ AZNPy Live Ticker - Investing.com
Investing.com· 3 days agoRisk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...
'Outstanding' Results for Osimertinib: Stage III EGFR+ NSCLC
Medscape· 4 days agoResults from the LAURA trial will change practice once its label gets expanded, experts said at the...